Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0388120050140020094
Journal of Korean Society for the Study of Obesity
2005 Volume.14 No. 2 p.94 ~ p.100
Effects of Voglibose and Glimepiride on Body weight in Patients with Type 2 Diabetes
Jung Sun-Hye

Kim Dae-Jung
Lee Kwan-Woo
Kim Bom-Taeck
Kim Sung-Soo
Kim Eun-Sook
Mok Ji-Oh
Ahn Chul-Woo
Yoon Hyun-Dae
Lee Sang-Yeoup
Lee Chang-Beom
Hong Seong-Bin
Abstract
Background: Obesity is a major risk factor for type 2 diabetes. Improvement in glycemic control using insulin, sulfonylurea and meglitinide is often accompanied by weight gain. But metformin and ¥á-glucosidase inhibitor have a positive effect(decrease) on weight. In this study, we compared the effect of voglibose, glimepiride, and diet alone on body weight and glycemic control after a period of 12 weeks.

Methods: The patients with type 2 diabetes were randomly assigned to one of the following three treatment
groups: Patients treated for 12 weeks with voglibose, those treated with glimepiride and those with diet alone. Anthropometric parameters and metabolic parameters were measured at the initial stage and after 12 weeks. The study consisted of 448 patients with type 2 diabetes. There were 223 patients in the voglibose group, 176 in the glimepiride group, and 49 in the diet alone group.

Results: The patients treated with voglibose and diet alone showed higher decreased body weight compared
with glimepiride group (voglibose vs glimepiride, P= 0.001; diet vs glimepiride, P= 0.016). In contrast, glimepiride group showed more decreased HbA1C compared with voglibose and diet alone groups (glimepiride vs voglibose, P= 0.001; glimepiride vs diet, P= 0.004).

Conclusion: Voglibose showed more effective on body weight reduction despite the relatively weak glycemic
control compared with glimepiride.
KEYWORD
Voglibose, Glimepiride, Body weight, Type 2 diabetes
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø